To expand these data, the aim of our study was to investigate the role of the HER receptor ligand system in the responsiveness of gastric cancer cells to cetuximab and trastuzumab, with special focus on AREG, transforming growth factor alpha (TGFα) and heparin-binding epidermal growth factor (HB-EGF). The gene discussed is TGFA; the disease is gastric cancer.